Welcome to our dedicated page for Transmedics Group news (Ticker: TMDX), a resource for investors and traders seeking the latest updates and insights on Transmedics Group stock.
TransMedics Group, Inc. reports developments in medical technology for organ transplant therapy, centered on its Organ Care System, or OCS, for preserving and monitoring donor lungs, hearts and livers outside the body. Company updates commonly cover OCS utilization through the National OCS Program, transplant logistics services, aviation fleet capacity, revenue trends and margin drivers.
Recurring news also includes clinical and regulatory disclosures tied to OCS programs and the Controlled Hypothermic Organ Preservation System, tax-accounting updates, material agreements, governance actions and employee equity awards. These developments reflect the company's commercial-stage model in organ preservation, transplant logistics and transplant-service support.
On February 20, 2023, TransMedics Group (NASDAQ: TMDX) granted non-qualified stock options for 72,774 shares and restricted stock units for 17,092 shares to new employees as part of their inducement to join the company. The options have an exercise price of $66.10, equivalent to the closing price on February 17, 2023. Vesting for the stock options occurs over four years, while the restricted stock units vest over the first four anniversaries of employment. These grants were authorized by the Compensation Committee in compliance with Nasdaq Listing Rule 5635(c)(4).
TransMedics Group, Inc. (TMDX) reported significant financial growth in its Q4 and full-year 2022 results. Total revenue for Q4 reached $31.4 million, a remarkable 225% increase from Q4 2021, and the full-year revenue totaled $93.5 million, marking a 209% rise compared to 2021. Despite a net loss of $6.7 million for Q4, improved from $12.7 million in Q4 2021, the company continues to invest heavily in its Next Generation Organ Care System (OCS). For 2023, TransMedics anticipates revenue growth to $138 million to $145 million, reflecting an increase of 48% to 55% year-over-year.
TransMedics Group, a leader in organ transplant technology, announced participation in two major investor conferences. The company will engage in a fireside chat at the Cowen 43rd Annual Healthcare Conference on March 6, 2023, at 9:10 a.m. EST, and will present virtually at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023, at 12:00 p.m. EST. Both events will feature a live and archived webcast accessible through the TransMedics investor website. TransMedics focuses on innovative solutions to enhance organ transplant therapies for patients facing end-stage organ failure.
TransMedics Group, Inc. (NASDAQ: TMDX) will announce its fourth quarter and full year 2022 financial results on February 22, 2023, after market close. A conference call will follow at 4:30 p.m. ET. Investors can access the call by dialing (866) 807-9684 domestically or (412) 317-5415 internationally. TransMedics specializes in portable extracorporeal warm perfusion and organ assessment technology, aimed at improving organ transplantation outcomes for patients suffering from end-stage heart, lung, and liver diseases.
TransMedics Group, Inc. (NASDAQ: TMDX) has appointed Nick Corcoran as Senior Vice President of Supply Chain and Operations, effective immediately. With 20 years of experience in global supply chain and commercial operations, including roles at Stryker Corporation, Corcoran will enhance TransMedics' operational efficiency to meet rising demand for OCS products. CEO Waleed Hassanein expressed confidence in Corcoran's ability to drive growth and optimize operations. TransMedics focuses on transforming organ transplant therapy through innovative technology, with headquarters in Andover, Massachusetts.
TransMedics Group, Inc. (Nasdaq: TMDX) announced its management team's presentation at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 5:15 p.m. PST. The event will focus on TransMedics' innovative organ transplant therapies for patients with end-stage organ failures. A live and archived webcast will be available on their website. Established in Andover, Massachusetts, TransMedics leads in portable extracorporeal warm perfusion, aiming to enhance donor organ preservation and viability.
On November 2, 2022, TransMedics Group, Inc. (NASDAQ: TMDX) announced the granting of non-qualified stock options for 138,400 shares to six new employees as an inducement for their employment. This was approved by the Compensation Committee in compliance with Nasdaq Listing Rule 5635(c)(4). Each option has an exercise price of $46.36, reflecting the stock's closing price on the grant date. Vesting will occur at 25% after one year, with the remainder vesting monthly over three years, tied to continued employment.
TransMedics reported a net revenue of $25.7 million for Q3 2022, marking a 378% increase compared to Q3 2021. Revenue comprises $24.3 million in sales and a $1.4 million favorable adjustment. The company raised its 2022 revenue guidance to between $80 million and $85 million, reflecting 164% to 181% growth year-over-year. Gross margin improved to 71%, while operating expenses rose to $23.7 million. Despite a net loss of $7.4 million, cash reserves stand at $204.5 million.
TransMedics Group, Inc. (TMDX) will release its third-quarter 2022 financial results on November 3, 2022, after market close. A conference call is set for 4:30 p.m. ET to discuss the results, accessible via phone or through a live webcast on their website. TransMedics specializes in organ transplant technology, focusing on improving organ quality and viability for patients with end-stage heart, lung, and liver failure.
TransMedics Group, Inc. (Nasdaq: TMDX), a leader in organ transplant technology, will participate in the Morgan Stanley 20th Annual Global Healthcare Conference. The event is scheduled for September 12, 2022, at 11:40 a.m. ET at the Sheraton New York. The management team will engage in a fireside chat, which will be accessible via a live and archived webcast on the company's investors' webpage.
TransMedics focuses on enhancing organ quality and viability assessments to improve transplant outcomes for patients with end-stage organ failure.